Advanced / Aggressive Protocol (1 mL = ~10.0 mg/mL)
| Phase |
Weekly Dose |
Units (per measurement) (mL) |
Vials Needed |
| Weeks 1–4 |
2 mg (2000 mcg) |
20 units (0.20 mL) |
1 vial per dose |
| Weeks 5–8 |
4 mg (4000 mcg) |
40 units (0.40 mL) |
1 vial per dose |
| Weeks 9–12 |
8 mg (8000 mcg) |
80 units (0.80 mL) |
1 vial per dose |
| Weeks 13+ |
12 mg (12000 mcg) |
120 units (1.20 mL) |
2 vials per dose** |
Note: The 12 mg dose represents the highest dose tested in Phase 2 trials[3][4], producing maximum weight-loss efficacy (~24% body weight at 48 weeks). **The 12 mg dose requires reconstituting 2 vials (each with 1.0 mL); draw 1.20 mL total from the combined 2.0 mL and split into 2 measurements at separate sites. Gradual titration is critical to minimize gastrointestinal observations[6].
Important: This guide is for educational purposes only and is not medical advice. Retatrutide is not FDA-approved and is available only for research use. All measurement must follow trial protocols.
How This Works
Retatrutide’s unique mechanism of action stems from its triple-agonist design. By activating GLP-1 and GIP receptors, it enhances insulin secretion (when glucose is present) and suppresses appetite, similar to existing incretin therapies[7][8]. Additionally, Retatrutide’s glucagon receptor agonism raises metabolic rate and promotes energy expenditure, further amplifying fat burning and weight loss beyond GLP-1/GIP effects alone[7]. The peptide is engineered with a fatty-acid moiety to extend its circulation time (half-life ~6 days), allowing for once-weekly measurement[2]. The combined hormonal activation leads to reduced calorie intake, increased satiety, and enhanced lipid oxidation, yielding potent weight loss and glycemic control[8][9]. Preclinical studies confirmed that adding glucagon activity helps counteract the body’s adaptive slowing of metabolism during weight loss[7]. In essence, Retatrutide tackles three metabolic pathways at once, resulting in greater efficacy in lowering blood glucose and body fat than single- or dual-agonist therapies.
References
The Lancet (2023)
— Rosenstock J, et al. Retatrutide for type 2 diabetes: Phase 2 trial results (36-week study, HbA1c reductions, weight loss)
New England Journal of Medicine (2023)
— Jastreboff AM, et al. Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss)
American Diabetes Association (2023)
— ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data)
ADA Meeting News (2023)
— Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage)
ClinicalTrials.gov
— Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760; protocol details, measurement regimens)
Current Obesity Reports (2025)
— Hamza M, et al. Triple agonism based therapies for obesity (review; titration strategies, GI observation management)
Cell Metabolism (2022)
— Coskun T, et al. LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism)
Nature Reviews Endocrinology (2024)
— Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation)
View Source
Diabetes Care (2024)
— Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure)
NEJM (2023) — Supplementary Material
— Jastreboff et al. obesity trial: cardiometabolic markers, liver fat reduction, lipid profiles
Hepatology (2024)
— Triple agonists in NAFLD/NASH: hepatic steatosis resolution (preclinical and clinical evidence)
The Lancet (2023) — Supplementary Data
— Rosenstock et al. diabetes trial: adverse event profiles, GI tolerability, titration schedules
CDC
— Vaccine preparation: route (angle/site guidance; no aspiration required)
Johns Hopkins Arthritis Center
— How to give a measurement (technique, site rotation, sharps disposal)
NCBI Bookshelf
— Preparation of medication: measurements (aseptic technique, preparation)
GenScript Peptide Services
— Peptide storage and handling guidelines (lyophilized and reconstituted storage conditions, stability)
Journal of Pharmaceutical Sciences (2018)
— Stability of peptides during freeze-thaw cycles (best practices for aliquoting and storage)
